Thermo Fisher Scientific Inc., the world leader in serving science, today announced the completion of Olink Explore HT proteomic analysis of approximately 5,500 research samples from The Michael J. Fox Foundation’s (MJFF) landmark study, the Parkinson’s Precision Medicine Initiative (PPMI). The resulting data are now in PPMI’s data repository, where they are available to the global research community.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Eyonis Inc., a Median Technologies company focused on applying artificial intelligence to the early detection and diagnosis of cancer, today announced that Median Technologies has entered into a strategic commercial agreement with Olea Medical, a Canon Medical Systems company, that will expand U.S. access to eyonis® LCS Lung Cancer Screening. The broader agreement also covers Europe and other markets that may be mutually agreed upon over time.

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Intelligenome and Cornell University entered into a research and development subaward agreement to support the development of a rapid, low-cost, and portable diagnostic solution for tuberculosis (TB), according to the company. The project is part of a National Institutes of Health (NIH) funded program focused on improving access to technologies for human healthcare.

Alveo Technologies, Inc. (Alveo), a leader in portable molecular sensing solutions, today announced a strategic partnership with The University of Texas Medical Branch (UTMB) to develop point-of-care diagnostics for viral hemorrhagic fevers across West Africa. The point-of-care diagnostic will provide real-time pathogen detection at clinical sites in Nigeria and Sierra Leone, supporting UTMB's Lassa fever research program—a major international initiative.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

NanoSomiX, Inc., a biotechnology company focused on blood‑based analytics using extracellular vesicles (EVs), including brain‑derived EVs, today announced plans to collaborate with Beckman Coulter Diagnostics, a global leader in clinical diagnostics, to explore the development of next‑generation immunoassays for neurodegenerative diseases.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.